日本語フィールド
著者：Sho Okamoto, Hiroshi Ureshino, Keisuke Kidoguchi, Kana Kusaba, Haruna Kizuka-Sano, Haruhiko Sano, Atsujiro Nishioka, Kyosuke Yamaguchi, Kazuharu Kamachi, Hidekazu Itamura, Mariko Yoshimura, Masako Yokoo, Takero Shindo, Yasushi Kubota, Toshihiko Ando, Kensuke Kojima, Atsushi Kawaguchi, Eisaburo Sueoka, Shinya Kimura題名：Clinical impact of the CONUT score in patients with multiple myeloma発表情報：Ann Hematol 巻: 99 号: 1 ページ: 113-119キーワード：概要：Novel anti-myeloma drugs have significantly improved the overall survival (OS) of patients with multiple myeloma (MM). However, not all MM patients treated with these drugs show survival benefits, and biologic and genetic prognostic factors are insufficient to predict the response to treatment. Decreasing treatment-related complications is important to improve the efficacy of treatment in patients with MM. The Controlling Nutritional Status (CONUT) score is a screening method for poor nutritional status, which is associated with poor prognosis in several cancers because it increases the rate of treatment-related complications. We retrospectively analyzed the OS of 64 patients with symptomatic MM and evaluated the correlation between the CONUT score and patient prognosis in MM. The median age at diagnosis was 66 years, and multivariate analysis showed that a high CONUT score (≥ 5; hazard ratio, 3.937; 95% confidence interval, 1.214-12.658; P = 0.022) was an independent prognostic risk factor. Subgroup analysis was performed according to patient age because the choice of treatment strategy, particularly autologous peripheral blood stem cell transplantation (auto-PBSCT), can vary depending on age in MM patients. Younger patients (< 65 years old) who received auto-PBSCT and had a lower CONUT score (0-3) showed a significantly better survival outcome than those with a higher CONUT score (≥ 4) (median OS, not reached vs. 64.1 months; P = 0.011). The CONUT score is simple to calculate and provides a useful prognostic indicator in patients with MM, especially transplant-eligible patients.抄録：英語フィールド
Author：Sho Okamoto, Hiroshi Ureshino, Keisuke Kidoguchi, Kana Kusaba, Haruna Kizuka-Sano, Haruhiko Sano, Atsujiro Nishioka, Kyosuke Yamaguchi, Kazuharu Kamachi, Hidekazu Itamura, Mariko Yoshimura, Masako Yokoo, Takero Shindo, Yasushi Kubota, Toshihiko Ando, Kensuke Kojima, Atsushi Kawaguchi, Eisaburo Sueoka, Shinya KimuraTitle：Clinical impact of the CONUT score in patients with multiple myelomaAnnouncement information:Ann Hematol Vol: 99 Issue: 1 Page: 113-119An abstract：Novel anti-myeloma drugs have significantly improved the overall survival (OS) of patients with multiple myeloma (MM). However, not all MM patients treated with these drugs show survival benefits, and biologic and genetic prognostic factors are insufficient to predict the response to treatment. Decreasing treatment-related complications is important to improve the efficacy of treatment in patients with MM. The Controlling Nutritional Status (CONUT) score is a screening method for poor nutritional status, which is associated with poor prognosis in several cancers because it increases the rate of treatment-related complications. We retrospectively analyzed the OS of 64 patients with symptomatic MM and evaluated the correlation between the CONUT score and patient prognosis in MM. The median age at diagnosis was 66 years, and multivariate analysis showed that a high CONUT score (≥ 5; hazard ratio, 3.937; 95% confidence interval, 1.214-12.658; P = 0.022) was an independent prognostic risk factor. Subgroup analysis was performed according to patient age because the choice of treatment strategy, particularly autologous peripheral blood stem cell transplantation (auto-PBSCT), can vary depending on age in MM patients. Younger patients (< 65 years old) who received auto-PBSCT and had a lower CONUT score (0-3) showed a significantly better survival outcome than those with a higher CONUT score (≥ 4) (median OS, not reached vs. 64.1 months; P = 0.011). The CONUT score is simple to calculate and provides a useful prognostic indicator in patients with MM, especially transplant-eligible patients.